Research Topics Immunology and DNA Vaccination

Research Area/ Research Interest: Immunology and DNA Vaccination

Research Paper Topics for Masters and Ph.D. Thesis and publication

  1. Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials
  2.  Two bicistronic DNA vaccines against Vibrio anguillarum and the immune effects on flounder Paralichthys olivaceus
  3. Hyperinflammation after anti-SARS-CoV-2 mRNA/DNA vaccines successfully treated with anakinra: Case series and literature review
  4. Preclinical evaluation of a precision medicine approach to DNA vaccination in type 1 diabetes
  5.  Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
  6. Principles in Immunology for the Design and Development of Vaccines
  7. A brief review on DNA vaccines in the era of COVID-19
  8. Fundamentals of Fish Vaccination
  9. Design and Preparation of Solid Lipid Nanoparticle (SLN)-Mediated DNA Vaccines
  10. Immune profile and responses of a novel Dengue DNA vaccine encoding EDIII-NS1 consensus design based on Indo-African sequences
  11. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models
  12.  Liposomes as immunological adjuvants and delivery systems in the development of tuberculosis vaccine: A review
  13.  Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines
  14. Preparation of antibodies against TXR1 and construction of a new DNA tumor vaccine
  15.  Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human 伪-synuclein: prelude for IND enabling studies
  16. pDNA and mRNA vaccines
  17. Glycosylation as a key parameter in the design of nucleic acid vaccines
  18. Use of Optical In Vivo Imaging to Monitor and Optimize Delivery of Novel Plasmid-Launched Live-Attenuated Vaccines
  19. Comparative immunology of agricultural birds
  20. Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases
  21. Development and Evaluation of DNA Vaccine Against Salmonid Alphavirus
  22. An overview of progress from empirical to rational design in modern vaccine development, with an emphasis on computational tools and immunoinformatics …
  23. A global survey in the developmental landscape of possible vaccination strategies for COVID-19
  24. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
  25. Immunological Assessment of Chitosan or Trimethyl Chitosan-Coated PLGA Nanospheres Containing Fusion Antigen as the Novel Vaccine Candidates Against …
  26.  Vaccination and immunotherapies in neuroimmunological diseases
  27.  Evaluation of Tuberculosis Vaccine Candidate, pcDNA3. 1-rpfD using Mycobacterial Growth Inhibition Assay (MGIA)
  28. Immunoinformatics and reverse vaccinology methods to design peptide-based vaccines
  29.  Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
  30. COVID-19: immunology, immunopathogenesis and potential therapies
  31. Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis
  32. Insight of oral vaccines as an alternative approach to health and disease management: An innovative intuition and challenges
  33.  Brief report on a phase I/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension
  34. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo …
  35. … largemouth bass (Micropterus salmoides) are more susceptible and vulnerable to Ichthyophthirius multifiliis infections: Immunological and histopathological study
  36. Practical aspects of poultry vaccination
  37. Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
  38. Vaccine and vaccination as a part of human life: In view of COVID‐19
  39. Vaccines to Prevent Diseases in Aquaculture
  40. … of Hemorrhagic Septicemia in 41 Countries in 2005–2019: A Systematic Analysis with Special Focus on the Potential Development of a New-Generation Vaccine
  41. Engineering immunity via skin-directed drug delivery devices
  42.  Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity
  43. Bactericidal efficacy of non-thermal plasma activation against Aeromonas hydrophila and immunological responses of koi (Cyprinus carpio haematopterus)
  44. Overview of vaccine adjuvants
  45. Establishment and characterization of a permanent heart cell line from largemouth bass Micropterus salmoides and its application to fish virology and immunology
  46.  Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies
  47. Teleost Fish as an Experimental Model for Vaccine Development
  48.  Active immunization combined with cisplatin confers enhanced therapeutic protection and prevents relapses of HPV-induced tumors at different anatomical …
  49. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice
  50. Computational approaches for vaccine designing
  51.  Designing and Modelling of Trivalent Chimeric Vaccine for Capripoxvirus: Lumpy Skin Disease, Sheep Pox and Goat Pox by Immunoinformatics Approach
  52. The Effect of Recombinant Protein Production in Lactococcus lactis Transcriptome and Proteome
  53.  Vaccines for gastrointestinal parasites, a pillar of preventive medicine in veterinary practice: Systematic review
  54. Engineering DNA Nanostructures to Manipulate Immune Receptor Signaling and Immune Cell Fates
  55. Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China
  56. COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts
  57. COVID-19 infection: concise review based on the immunological perspective
  58. Neoantigens and their potential applications in tumor immunotherapy
  60.  Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models
  61. Revisiting the Principles of Designing a Vaccine
  62. Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
  63.  Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using …
  64. Viral-vectored vaccines against SARS-CoV-2
  65. Development of peptide vaccine candidate using highly antigenic PE-PGRS family proteins to stimulate the host immune response against Mycobacterium …
  66.  Supplement to Vaccine 1998 Volume 17 Number 5 XII
  67. Immunoinformatics analysis for design of multi-epitope subunit vaccine by using heat shock proteins against Schistosoma mansoni
  68. Development of the Antileishmanial Vaccine
  69. Enantiomer-dependent immunological response to chiral nanoparticles
  70. Mucosal delivery of mannose functionalized biomimetic nanoparticles via the branchial route induces robust mucosal and systemic immune responses against fish …
  71.  T-cell epitope-based vaccine designing against Orthohantavirus: a causative agent of deadly cardio-pulmonary disease
  72. Oral Vaccination With Recombinant Pichia pastoris Expressing Iridovirus Major Capsid Protein Elicits Protective Immunity in Largemouth Bass (Micropterus salmoides …
  73.  Recent advances in immunocastration in sheep and goat and its animal welfare benefits: A review
  74. Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies
  75.  Role and relevance of fish cell lines in advanced in vitro research
  76. Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination …
  77. Immune Response of a Polyvalent Parenteral Vaccine Against Pathogenic Escherichia Coli that Induced Long-Lasting Adaptive Immunity in Pigs
  78. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
  79. The search for a Buruli Ulcer vaccine and the effectiveness of the Bacillus Calmette–Guérin vaccine
  80. Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies
  81. Built-in adjuvants for use in vaccines
  82.  Precision Vaccine Development: Cues From Natural Immunity
  83.  Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2
  84.  Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy
  85. Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
  86. Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2
  87. The Regulatory Evaluation of Vaccines for Human Use
  88.  A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
  89. New‐onset autoimmune phenomena post‐COVID‐19 vaccination
  90. Immunological Biomarker Discovery in Cure Regimens for Chronic Hepatitis B Virus Infection
  91. A novel low-molecular-weight chitosan/gamma-polyglutamic acid polyplexes for nucleic acid delivery into zebrafish larvae
  92.  Microneedle systems for delivering nucleic acid drugs
  93. A review of the antiviral activity of Chitosan, including patented applications and its potential use against COVID‐19
  94. The immunology of low-grade gliomas
  95.  The year that shaped the outcome of the OspA vaccine for human Lyme disease
  96. Accelerating research and development of new vaccines against tuberculosis: a global roadmap
  97. Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines
  98.  Host immunity and vaccine development against Dengue virus
  99.  Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
  100.  Advanced materials for the delivery of vaccines for infectious diseases
  101. Brucella antigens (BhuA, 7α-HSDH, FliC) in poly I: C adjuvant as potential vaccine candidates against brucellosis
  102. Advanced Materials for SARS‐CoV‐2 Vaccines
  103.  Innate response of rainbow trout gill epithelial (RTgill-W1) cell line to ultraviolet-inactivated VHSV and FliC and rhabdovirus infection
  104. Microneedles enable the development of skin-targeted vaccines against coronaviruses and influenza viruses
  105. Identification of immunodominant epitopes on nucleocapsid and spike proteins of the SARS-CoV-2 in Iranian COVID-19 patients
  106.  Immunization With Recombinant Haemonchus contortus Y75B8A. 8 Partially Protects Local Crossbred Female Goats From Haemonchus contortus Infection
  107.  Prokaryotic Expression of the Toxoplasma gondii SAG2 Gene in Pet Cats and Establishment of an Indirect ELISA Method
  108. Immunological Cross-Reactivity to Dengue Virus among Persons with Neuroinvasive West Nile Virus Infection
  109.  Peptide-based vaccines for tuberculosis
  110. Visualization of drug delivery via tattooing: effect of needle reciprocating frequency and fluid properties
  111. The race for a COVID-19 vaccine: where are we up to?
  112.  An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses
  113. Designing of a multi-epitopes-based peptide vaccine against rift valley fever virus and its validation through integrated computational approaches
  114. In silico design of influenza a virus artificial epitope-based T-cell antigens and the evaluation of their immunogenicity in mice
  115.  A novel locally prepared inactivated bivalent mycoplasma vaccine for chicken flocks in Egypt
  116. Design of a Multi-Epitopes Vaccine against Hantaviruses: An Immunoinformatics and Molecular Modelling Approach
  117. Translational Development and Testing of Theranostics in Combination with Immunotherapies
  118.  Biodistribution and immunity of adenovirus 5/35 and modified vaccinia Ankara vector vaccines against human immunodeficiency virus 1 clade C
  119.  The Future of Nanoscience: Where To, Where From?
  120. The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines
  121.  Immunogenicity of a Recombinant VSV-Vectored SARS-CoV Vaccine Induced Robust Immunity in Rhesus Monkeys after Single-Dose Immunization
  122. Innovative vaccine approaches—a Keystone Symposia report
  123.  Nucleic acid functionalized extracellular vesicles as promising therapeutic systems for nanomedicine
  124.  Characterisation of tetraspanins from Schistosoma haematobium and evaluation of their potential as novel diagnostic markers
  125. SARS‐CoV‐2 variants and vulnerability at the global level
  126.  COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines
  127.  Emerging vaccine nanotechnology: From defense against infection to sniping cancer
  128. Dendrimers in vaccine delivery: Recent progress and advances
  129. Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of …
  130. Production of Properly Folded NS1 Protein in Bacterial Cells
  131.  … , and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in …
  132. Designing a novel multiepitope peptide vaccine against melanoma using immunoinformatics approach
  133.  Advancements of common gamma-chain family cytokines in cancer immunotherapy
  134. An update on preclinical pregnancy models of Zika virus infection for drug and vaccine discovery
  135.  Strategies for successful designing of immunocontraceptive vaccines and recent updates in vaccine development against sexually transmitted infections-A …
  136. Immunogenic profiling of Mycobacterium tuberculosis DosR protein Rv0569 reveals its ability to switch on Th1 based immunity
  137. Effective improvements to the live-attenuated Newcastle disease virus vaccine by polyethylenimine-based biomimetic silicification
  138. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine
  139. Human genetic and immunological determinants of critical COVID-19 pneumonia
  140. Production of Properly Folded NS1 Protein in Bacterial Cells
  141.  … , and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in …
  142. Designing a novel multiepitope peptide vaccine against melanoma using immunoinformatics approach
  143.  Advancements of common gamma-chain family cytokines in cancer immunotherapy
  144. An update on preclinical pregnancy models of Zika virus infection for drug and vaccine discovery
  145.  Strategies for successful designing of immunocontraceptive vaccines and recent updates in vaccine development against sexually transmitted infections-A …
  146. Immunogenic profiling of Mycobacterium tuberculosis DosR protein Rv0569 reveals its ability to switch on Th1 based immunity
  147. Effective improvements to the live-attenuated Newcastle disease virus vaccine by polyethylenimine-based biomimetic silicification
  148. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine
  149. Human genetic and immunological determinants of critical COVID-19 pneumonia
  150.  Vaccine efficacy and SARS-CoV-2 control in California and US during the session 2020–2026: A modeling study
  151. STxB as an Antigen Delivery Tool for Mucosal Vaccination
  152. The variants of SARS‐CoV‐2 and the challenges of vaccines
  153. A global picture: therapeutic perspectives for COVID-19
  154. Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
  155.  Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
  156.  Virtual Events
  157.  COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine …
  158.  Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis
  159.  A D-peptide-based HIV gelatinous combination vaccine improves therapy in ART-delayed macaques of chronic infection
  160. Lack of evidence for intergenerational inheritance of immune resistance to infections
  161. Discovery of B-cell epitopes for development of dengue vaccines and antibody therapeutics
  162. Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines
  163. Genetics and Vaccine development for SARS-CoV2 in the era of Personalized Medicine
  164. Avian cytokines and their receptors
  165. Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial
  166. Structure-guided design of multi-epitopes vaccine against variants of concern (VOCs) of SARS-CoV-2 and validation through In silico cloning and immune simulations
  167.  New-onset systemic lupus erythematosus after mRNA SARS-CoV-2 vaccination
  168.  Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection
  169. Cellular Immune Response after Vaccination in Patients with Cancer—Review on Past and Present Experiences
  170. Tick-borne encephalitis nonstructural protein NS1 expressed in E. coli retains immunological properties of the native protein
  171. Efficacy and safety of heterologous booster vaccination with Ad26. COV2. S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no …
  172. mRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology
  173. Immunological characterization of rLdTCP1γ for its prophylactic potential against visceral leishmaniasis in hamster model
  174. Animal models in vaccinology: state of the art and future perspectives for an animal-free approach
  175. Developments in Vaccine Adjuvants
  176.  Pre-vaccination frequency of circulatory Tfh is associated with robust immune response to TV003 dengue vaccine
  177. A quantum vaccinomics approach based on protein–protein interactions
  178. The avian enteric immune system in health and disease
  179. Mucosal Vaccination with Cyclic Dinucleotide Adjuvants Induces Effective T Cell Homing and IL-17–Dependent Protection against Mycobacterium tuberculosis …
  180. Adaptive Immune Responses, Immune Escape and Immune-Mediated Pathogenesis during HDV Infection
  181.  Immunological perspective: Helicobacter pylori infection and gastritis
  182. Novel Mouse Models for Cancer Immunology
  184.  Immunogenicity and protective efficacy of an inactivated SFTS vaccine candidate in mice
  185. Mucosal immunology in fish
  186. Repetitive DNA in disease
  187.  Nanotechnology in aquaculture: Applications, perspectives and regulatory challenges
  188. The Importance of Cellular Immune Response to HIV: Implications for Antibody Production and Vaccine Design
  189. Engineered devices for tumor microenvironment immune modulation
  190.  Differential immunogenicity of homologous versus heterologous boost in Ad26. COV2. S vaccine recipients
  191. Abstract P006: Intratumoral electroporation of IL-12 and SARS-Cov-2 spike plasmids drives a coordinated vaccine response and elicits robust anti-tumor immunity
  192. Immunology in the Fetus and Neonate
  193.  Glycobiology in Innate Immunology
  194. Flavanol Consumption in Healthy Men Preserves Integrity of Immunological‐Endothelial Barrier Cell Functions: Nutri (epi) genomic Analysis
  195. Novel immunotherapeutic approaches to cancer: voltage-gated sodium channel expression in immune cells and tumors
  196. Novel Neutralizing Epitope of PEDV S1 Protein Identified by IgM Monoclonal Antibody
  197. Screening of potential antigens from whole proteome and development of multi-epitope vaccine against Rhizopus delemar using immunoinformatics approaches
  198.  Protein-based biomaterials for combating viral infections: current status and future prospects for development
  199. Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options
  200. Pathology and Anticatalytic Treatment of Exacerbated COVID-19
  201.  Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose …
  202. A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus
  203. Immunological Mechanisms of Probiotics in Chickens
  204. A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection
  205. A review on the effect of prolyl isomerization on immune response aberration and hypersensitivity reactions: A unifying hypothesis
  206. Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity
  207. BCG vaccination induces cross-protective immunity against pathogenic microorganisms
  208. Preclinical Assessment of the Immunogenicity of Experimental Leishmania Vaccines
  209. Immunization of chickens with Salmonella Gallinarium ghosts expressing Salmonella Enteritidis NFliC-FimAC and CD40LC fusion antigen enhances cell-mediated …
  210.  Therapeutic vaccines for breast cancer: Has the time finally come?
  211. Nanoscale Vaccines: Design, Delivery, and Applications
  212. LDH nanoparticle adjuvant subunit vaccine induces an effective immune response for porcine epidemic diarrhea virus
  213. Nanozyme-based enhanced cancer immunotherapy
  214.  Prediction and evaluation of multi epitope based sub-unit vaccine against Salmonella typhimurium
  215.  In silico construction of a multiepitope Zika virus vaccine using immunoinformatics tools
  216. SARS‐CoV‐2 and influenza viruses: Strategies to cope with coinfection and bioinformatics perspective
  217. Multicomponent Plasmid Protects Mice From Spontaneous Autoimmune Diabetes
  218. Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity
  219.  Selenium and protozoan parasitic infections: selenocompounds and selenoproteins potential
  220. Pattern recognition receptors
  221. Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes
  222. Preparation of hyaluronic acid-coated polymeric micelles for nasal vaccine delivery
  223.  Vaccine protection against the SARS-CoV-2 Omicron variant in macaques
  224. Designing AbhiSCoVac-A single potential vaccine for all ‘corona culprits’: Immunoinformatics and immune simulation approaches
  225. Liposome-Mediated Delivery of MERS Antigen Induces Potent Humoral and Cell-Mediated Immune Response in Mice
  226.  Applications of chitosan and chitosan nanoparticles in fish aquaculture
  227. Anterior uveitis following COVID vaccination: A summary of cases from Global Reporting Systems
  228. Acute‐onset polyradiculoneuropathy after SARS‐CoV2 vaccine in the West and North Midlands, United Kingdom
  229. Immunotherapeutic approaches to HIV cure and remission
  230. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
  231.  Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
  232. Dengue: current state one year before WHO 2010–2020 goals
  233. Vaccines Targeting Numerous Coronavirus Antigens, Ensuring Broader Global Population Coverage: Multi-epitope and Multi-patch Vaccines
  234.  BNT162b2 Vaccine Induces Divergent B cell responses to SARS-CoV-2 S1 and S2
  235. Effect of alginate nanoparticles on the immunogenicity of excretory-secretory antigens against acute toxoplasmosis in murine model
  236.  Immunoinformatics Approaches for Developing Multi-Epitope Subunit Vaccines to Combat Acinetobacter Baumannii
  237. Leite LCdC (2021) Systems Biology Analysis of the Radiation-Attenuated Schistosome Vaccine Reveals a Role for Growth Factors in Protection and Hemostasis …
  238. Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes
  239. Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients
  240. Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: real-world data
  241. Conventional and nontraditional delivery methods and routes of vaccine administration
  242. Expression and purification of S5196-272 and S6200-317 proteins from Tilapia Lake Virus (TiLV) and their potential use as vaccines
  243. Nanoparticle asymmetry shapes an immune response
  244. The prevalence of adaptive immunity to COVID-19 and reinfection after recovery–a comprehensive systematic review and meta-analysis
  245. Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups
  246. Plant-Based Vaccines: Antigen Design, Diversity, and Strategies for High Level Production
  247.  Feline panleukopenia virus DNA shedding following modified live virus vaccination in a shelter setting
  248. Stopping pandemics before they start: Lessons learned from SARS-CoV-2
  249. Structure and evolution of avian immunoglobulins
  250.  Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
  251. Llama DNA Immunization and Isolation of Functional Single-Domain Antibody Binders
  252. Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach
  253.  Microbiota regulation of viral infections through interferon signaling
  254.  A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions …
  255. Aetiopathogenesis, molecular determinants and immunological features
  256.  Vaccination of elite athletes against SARS-CoV-2 and broader implications for public health policy
  257. The avian respiratory immune system
  258.  Does CCL19 act as a double-edged sword in cancer development?
  259.  Prediction and analysis of multi epitope based vaccine against Newcastle disease virus based on haemagglutinin neuraminidase protein
  260.  BCG vaccination provides protection against IAV but not SARS-CoV-2
  261.  In-Silico Vaccine Design Based on a Novel Vaccine Candidate Against Infections Caused by Acinetobacter baumannii
  262.  Global Comprehensive Outlook of Hantavirus Contagion on Humans: A Review
  263.  … impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged …
  264. Tumor associated macrophage and microbe: The potential targets of tumor vaccine delivery
  265. Nanotechnology: A next-generation tool for sustainable aquaculture
  266.  … dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated …
  267.  Cloning and Expression of the Recombinant HPV16/18 L1-L2-E7 Polypeptide in Bacterial Expression System
  268. Prostate cancer immunotherapy
  269. Plant-Based Vaccines in Combat against Coronavirus Diseases.


Research Topics Biology